The IL-17/IL-23 axis seems to be involved in the pathogenesis of both psoriasis and lung fibrosis; also, biological agents inhibiting that pathway have been shown to improve both skin and lung lesions in some studies [30,35]. This evidence concerns the gene IL17A and pulmonary fibrosis.